Tag Archives: Incruse® (umeclidinium)

GlaxoSmithKline’s Incruse® (umeclidinium) gets European Commission marketing authorisation as maintenance bronchodilator treatment of COPD

London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Now licensed across … Read the full press release